Study guide
5.1 Collaborative Practice Agreements (CPAs) & Protocol-Based Care
NABP MPJE Multistate Pharmacy Jurisprudence Examination Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Pharmacist Licensure & Reciprocity
1.1 Initial Licensure Requirements & Examinations 1.2 License Renewal, Continuing Education (CE) & Status 1.3 Reciprocity, License Transfer & Multistate Licensure 1.4 Disciplinary Actions, Board Hearings, Sanctions & Reinstatement
2 Chapter 2: Pharmacy Personnel Roles & Supervision Ratios
2.1 Pharmacy Interns: Scope of Practice, Supervision & Preceptor Rules 2.2 Pharmacy Technicians: Registration, Certification & Permitted Duties 2.3 Technician-to-Pharmacist Ratios & Delegated Tasks 2.4 Non-Pharmacist Personnel & Automated Dispensing Technology Roles
3 Chapter 3: Prescriptive Authority & Practitioner Categories
3.1 Physicians, Dentists, Veterinarians & Podiatrists: Prescribing Scope 3.2 Mid-Level Practitioners: APNs, PAs, Optometrists & Independent Authority 3.3 Out-of-State, Foreign & Deceased Practitioner Prescriptions 3.4 Self-Prescribing & Prescribing for Family Members
4 Chapter 4: Patient Counseling & Drug Utilization Review (OBRA '90)
4.1 OBRA '90 Mandates & Prospective Drug Utilization Review (DUR) 4.2 Patient Counseling Requirements, Offer-to-Counsel & Documentation 4.3 Patient Profile Requirements & Retrospective DUR
5 Chapter 5: Advanced Pharmacist Practice & Collaborative Agreements
5.1 Collaborative Practice Agreements (CPAs) & Protocol-Based Care 5.2 Pharmacist Immunization Authority & Vaccine Administration Protocols 5.3 Medication Therapy Management (MTM) & Point-of-Care Testing (POCT) 5.4 Hormonal Contraceptive, Naloxone & Post-Exposure Prophylaxis (PEP/PrEP) Prescribing
6 Chapter 6: Federal Controlled Substances Act (CSA) & Scheduling
6.1 Controlled Substance Schedules (CI through CV) & Classification Criteria 6.2 DEA Registration: Types, Forms (224, 225, 363) & Renewal Cycles 6.3 Scheduled Listed Chemical Products (SLCPs) & Combat Methamphetamine Epidemic Act (CMEA)
7 Chapter 7: Controlled Substance Prescriptions & Legitimate Purpose
7.1 Corresponding Responsibility & Red Flags for Improper Prescribing 7.2 Required Components of Controlled Substance Prescriptions 7.3 Electronic Prescriptions for Controlled Substances (EPCS) & Security Requirements 7.4 Emergency Schedule II Prescriptions & Partial Filling Rules (CARA Act)
8 Chapter 8: Controlled Substance Ordering, Inventory & Recordkeeping
8.1 Ordering Schedule II Substances: CSOS & DEA Form 222 Execution 8.2 Controlled Substance Inventory Requirements (Initial, Biennial, Count Exactness) 8.3 Theft, Significant Loss (DEA Form 106) & Disposal/Destruction (DEA Form 41) 8.4 Prescription Transfers & Prescription Drug Monitoring Programs (PDMPs)
9 Chapter 9: Federal Pure Food, Drug & Cosmetic Act (FD&C Act) & Drug Safety
9.1 Adulteration vs. Misbranding: Statutory Definitions & Legal Violations 9.2 Prescription Labeling Requirements, Expiration Dates & Side Effect Statements 9.3 Poison Prevention Packaging Act (PPPA) & Child-Resistant Container Exemptions 9.4 Drug Recalls (Class I, II, III) & Market Withdrawals 9.5 Drug Product Selection, Generic Substitution & DAW Codes 9.6 Returning & Reusing Dispensed Drugs: Restocking, Redispensing & Repository Programs
10 Chapter 10: Drug Supply Chain Security Act (DSCSA) & Commercial Distribution
10.1 DSCSA Track-and-Trace Requirements: Transaction Information & Statements 10.2 Suspect & Illegitimate Product Verification, Quarantine & Notification 10.3 Prescription Drug Marketing Act (PDMA): Samples, Reimportation & Wholesale Distribution
11 Chapter 11: Compounding Standards: USP <795>, <797> & <800>
11.1 Section 503A vs. 503B Compounding Facilities (DQSA Architecture) 11.2 Non-Sterile Compounding (USP <795>) & Beyond-Use Dating (BUD) 11.3 Sterile Compounding (USP <797>): Air Quality, Cleanrooms & BUD 11.4 Hazardous Drug Handling (USP <800>): Engineering Controls & Personal Protective Equipment
12 Chapter 12: Pharmacy Operational Security, Records & Telepharmacy
12.1 Physical Pharmacy Security, Alarm Systems & Keyholder Rules 12.2 Mandatory Pharmacy Records Retention & Audit Inspection Readiness 12.3 Central Fill, Automated Dispensing Systems (ADS) & Telepharmacy Operations 12.4 HIPAA Privacy Rule, Patient Records & Breach Notification Protocols
5.1 Collaborative Practice Agreements (CPAs) & Protocol-Based Care
Key Takeaways Explain This Topic AI
Collaborative Practice Agreements (CPAs) create a legal framework allowing pharmacists to perform Collaborative Drug Therapy Management (CDTM) under prescriber supervision.
Scope of authorized pharmacist functions in a CPA includes initiating, modifying, and discontinuing therapy, as well as ordering and interpreting laboratory tests.
Patient-specific CPAs require individual patient referrals, whereas population-based CPAs cover any patient matching defined clinical criteria within a practice.
Pharmacists operating under a CPA must document all clinical interventions and lab orders in the shared patient record within 24 to 72 hours depending on state law.
Active CPAs require mandatory periodic written review (typically annual or biennial) signed by all participating prescribers and pharmacists, with records retained for 2 to 5 years after termination.
Last updated: July 2026
5.1 Collaborative Practice Agreements (CPAs) & Protocol-Based Care
MPJE Core Concept: A Collaborative Practice Agreement (CPA) is a formal legal agreement between one or more licensed pharmacists and one or more authorizing prescribers (MD, DO, or in some jurisdictions APNs/PAs) that expands the pharmacist's scope of practice to perform Collaborative Drug Therapy Management (CDTM). Under a CPA, pharmacists are authorized to initiate, modify, or discontinue drug therapy, order and interpret laboratory tests, and conduct disease-focused physical assessments within defined clinical boundaries.
1. Evolution and Legal Framework of CPAs
Collaborative Drug Therapy Management (CDTM) represents a progressive model of interprofessional healthcare delivery. State pharmacy practice acts govern the creation, scope, and enforcement of CPAs. While the specific legal mechanisms vary across jurisdictions, all 50 states and the District of Columbia recognize some form of collaborative practice authority.
Statutory Authority and Board Oversight
CPAs operate under joint regulatory oversight by state Boards of Pharmacy and state Medical Boards (or Nursing Boards when nurse practitioners participate).
Dual Jurisdiction: The pharmacy board regulates the pharmacist's clinical actions, while the medical board regulates the authorizing physician's delegation of medical authority.
Protocol Approval: Some state boards require formal registration or pre-approval of CPAs before implementation, while other states permit CPAs to take effect immediately upon written execution by all participating parties.
2. Structure of CPAs: Patient-Specific vs. Population-Based
The legal scope of a CPA is classified based on how patients are enrolled into collaborative care.
Feature Patient-Specific CPA Population-Based (Disease-State) CPA
Enrollment Trigger Requires an explicit written or electronic referral/order from the physician for an individual patient. Covers any patient within the prescriber's practice who meets predefined clinical inclusion/exclusion criteria.
Clinical Scope Tailored to the individual patient's medical condition and treatment plan. Standardized clinical protocol for specific chronic disease states (e.g., Type 2 Diabetes, Hypertension, Anticoagulation).
Prescriber Involvement High initial involvement; physician diagnoses and actively refers each patient. Systemic oversight; physician approves overall protocol and receives periodic updates on enrolled patients.
Common Practice Setting Ambulatory care clinics, specialty clinics, inpatient hospital care. Community pharmacy chains, health-system outpatient clinics, accountable care organizations (ACOs).
Regulatory Risk Lower regulatory scrutiny due to direct individual physician authorization. Higher regulatory scrutiny; requires precise inclusion/exclusion criteria and robust auditing procedures.
3. Mandatory Legal & Operational Elements of a CPA
To be legally binding and compliant with MPJE standards, a written CPA must contain specific statutory elements:
CPA Element Legal & Operational Requirement
Identified Parties Full legal names, license numbers, practice addresses, and contact details of all participating pharmacists and authorizing prescribers.
Authorized Scope of Services Specific drug classes, disease states, clinical decision algorithms, and clinical actions authorized (initiation, modification, discontinuation, lab ordering).
Clinical Protocols & Guidelines Evidence-based clinical guidelines (e.g., ACC/AHA hypertension guidelines, ADA diabetes standards) governing all pharmacological adjustments.
Lab Ordering Authority Specific laboratory tests authorized (e.g., HbA1c, serum creatinine, LFTs, INR, lipid panels) relevant to the managed disease state.
Documentation Timelines Mandatory entry of all clinical encounters, drug changes, and lab results into the shared electronic health record (EHR) within 24 to 72 hours (per state statute).
Prescriber Notification Explicit rules for immediate prescriber notification during acute events (e.g., severe hypoglycemia, organ dysfunction, drug toxicity).
Term & Renewal Schedule Defined effective date, mandatory periodic review schedule (typically annual or biennial sign-off), and explicit termination procedures.
Record Retention Requirement to retain executed copies of the CPA and all patient care documentation for 2 to 5 years post-termination.
4. Authorized Pharmacist Functions Under a CPA
Under a valid CPA, the pharmacist's scope of practice extends beyond traditional dispensing to encompass comprehensive clinical management:
Initiation of Therapy: Selecting and prescribing a specific drug, dose, route, and dosage form within authorized therapeutic categories (e.g., initiating insulin glargine for a diabetic patient with HbA1c > 9%).
Dose Modification & Titration: Adjusting maintenance doses based on therapeutic response, lab values, or adverse effects (e.g., titrating lisinopril from 10 mg to 20 mg daily for blood pressure control).
Therapeutic Substitution & Discontinuation: Switching within a drug class based on formulary availability or stopping ineffective/toxic medications.
Ordering & Interpreting Diagnostic Tests: Requesting blood work, urinalysis, or point-of-care testing necessary to evaluate drug efficacy and toxicity (e.g., ordering serum potassium levels after initiating spironolactone).
Physical Assessment: Performing non-invasive, disease-focused physical assessments (e.g., blood pressure measurement, foot examination in diabetes, pulse check, pulmonary auscultation).
- 5. Supervision, Delegation, and Quality Assurance
- Direct vs. Indirect Supervision
Indirect Supervision: Most outpatient and clinic CPAs permit indirect supervision, meaning the authorizing physician does not need to be physically present on-site while the pharmacist evaluates patients, provided the physician remains available via telecommunication.
Physical Presence Rules: Certain state statutes mandate physical presence for specific high-risk clinical procedures or when practicing in designated non-traditional settings.
Prohibition of Delegation
Pharmacists cannot delegate clinical decision-making, drug prescribing, or diagnostic interpretation authorized under a CPA to pharmacy technicians, pharmacy interns, or unlicensed staff. While interns may gather medical histories or perform health screenings under direct pharmacist supervision, the final clinical assessment and prescribing decision must be executed by the authorized CPA pharmacist.
6. Risk Management, Liability, and Board Compliance
Professional Liability Insurance: Pharmacists engaging in CPA-authorized clinical practice are typically required by state law or employer policy to maintain professional liability insurance with minimum limits of $1,000,000 per occurrence and $3,000,000 aggregate coverage .
Quality Assurance & Audits: CPAs must include a quality assurance plan requiring random chart audits by the authorizing physician (e.g., auditing 5% to 10% of patient records quarterly) to evaluate clinical outcomes and protocol compliance.
Revocation and Termination: Either party may terminate a CPA at any time by providing written notification. Upon termination, the pharmacist's prescribing authority for patients under that protocol immediately ceases, and care must be transferred back to the primary physician.